Floatz logo
Floatz Rating
BB68/100
Confidence
Indicative
v0.2
Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05849298CT.gov
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
—Active Not Recruiting———
NCT04689828CT.gov
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
—Active Not Recruiting———
NCT04720157CT.gov
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
—Active Not Recruiting———
NCT03822845CT.gov
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
—Completed———
NCT03183544CT.gov
Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit
—Completed———
NCT04050215CT.gov
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
—Completed———
NCT03389451CT.gov
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
—Completed———
NCT03388346CT.gov
68Ga PSMA in Preprostatectomy Patients
—Completed———
NCT02952469CT.gov
Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
—Completed———
NCT04452136CT.gov
Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer
—Approved For Marketing———
Show 1 more trial
NCT04854369CT.gov
68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)
—No Longer Available———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Prostate Neoplasm

AssetSponsorPhaseRating
Gozetotide (this asset)Telix Pharmaceuticals (Innovations) Pty LimitedP3BB · 68
DocetaxelMerck Sharp & Dohme LLCP4BBB
PrednisoneMerck Sharp & Dohme LLCP3BBB
DegarelixNovartis PharmaceuticalsP4BBB
AbirateroneQilu Pharmaceutical Co., Ltd.P3BB
LeuporelinDana-Farber Cancer InstituteP4BB
Radium Ra-223BayerP3BB
PrednisoloneEli Lilly and CompanyP3BB
ApalutamideBayerP4BB

+42 more in the Prostate Neoplasm cohort

Other indications for Gozetotide

IndicationSponsorPhaseRating
Prostate Cancer—P3BB · 66
Metastatic Prostate Carcinoma—UnkC · 35
Prostate Disorder—UnkD · 30

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Gozetotide in Prostate Neoplasm. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/gozetotide-prostate-neoplasm

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →